NEW YORK ─ Life sciences firm LGC said on Thursday that it has acquired infectious-disease antigen and antibody supplier Native Antigen Company (NAC) for an undisclosed amount.
Teddington, UK-based LGC said the deal strengthens its product offering to the IVD sector, which includes a range of quality assurance tools, immunoassay reagents, disease-state plasma, and probes and primers for molecular diagnostic tests.
The acquisition will enable LGC to provide an expanded portfolio of reagents, Michael Sweatt, executive VP and general manager for clinical diagnostics at the firm, said in a statement. "NAC’s focus on infectious disease is highly complementary with our existing offer to this segment comprising controls, reference materials, MDx tools, and other components."
Oxford, UK-based NAC develops, manufactures, and supplies reagents for the in vitro diagnostic, pharmaceutical, and academic sectors, including antigens for SARS-CoV-2. It offers native and recombinant infectious disease antigens and related products, including pathogen receptors, virus-like particles, and antibodies for immunoassays, vaccine development, and quality-control products. The firm's portfolio includes more than 60 viral and infectious disease products, with applications for dengue, cytomegalovirus, Zika, chikungunya, and Clostridium difficile, LGC said.